Online inquiry

IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3484MR)

This product GTTS-WQ3484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Pseudomonas aeruginosa infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3484MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10999MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ5573MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ7290MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-008
GTTS-WQ4474MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ7878MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ12135MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ6388MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ1095MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW